top of page
Search

Nicotine’s Structural Break Is Underway

  • Writer: Sydwell Rammala
    Sydwell Rammala
  • Mar 15
  • 15 min read

Updated: Apr 6

Building a Portfolio for the Post-Combustion Era

The global nicotine industry is presently navigating a structural transformation that mirrors the decarbonization efforts seen in the energy sector. This "Nicotine Transition" represents a fundamental pivot from combustible delivery systems, which have dominated public consumption for over a century, toward a sophisticated ecosystem of smokeless alternatives including heated tobacco systems (HTS), modern oral nicotine pouches, electronic vapor products, and pharmaceutical-grade nicotine replacement therapies (NRT). For institutional investors, this transition is not merely a public health evolution but a complete reconfiguration of industry cash flow durability and terminal value. The shift requires a nuanced analysis of how legacy tobacco giants leverage their existing pricing power to fund the research, development, and commercialization of next-generation products (NGP) that promise a more sustainable and less litigious long-term revenue profile.1


1. Introduction: The Strategic Revaluation of Nicotine

The central thesis of the Nicotine Transition is that the industry is successfully decoupling the consumer’s desire for nicotine from the harmful chemical byproducts of tobacco combustion. This decoupling is creating a new category of "reduced-risk products" (RRP) that exhibit different growth trajectories and regulatory risk profiles compared to traditional cigarettes. Much like the energy transition involves a move from high-carbon fossil fuels to low-carbon renewables, the nicotine industry is migrating its consumer base to platforms that provide a similar sensorial experience with a significantly improved toxicological profile.3


The traditional investment narrative for tobacco focused on "harvesting" cash through extreme pricing power in a declining volume environment. However, the post-combustion era introduces a growth component. Companies that have successfully scaled their smoke-free portfolios are beginning to see a "mix upgrade," where units of smokeless products generate higher net revenues and gross profits per unit than cigarettes. By the end of fiscal year 2025, leaders like Philip Morris International (PMI) demonstrated that smoke-free products can account for more than 40% of total group revenue, fundamentally changing the company’s valuation from a legacy manufacturer to a high-growth consumer technology player.1


2. The Financial Power of Tobacco: Funding the Transition Bridge

The financial resilience of the tobacco industry provides the necessary capital to cross the "combustible bridge." High operating margins and consistent free cash flow (FCF) are the primary engines for the multi-billion dollar R&D investments required to navigate the premarket tobacco product application (PMTA) and modified risk tobacco product (MRTP) pathways.1

Institutional Financial Benchmarks: FY 2025 Snapshot


Metric

Altria Group

British American Tobacco (BAT)

Philip Morris International (PMI)

Japan Tobacco (JT)

Adjusted Operating Margin

62.4% 9

44.0% 10

40.4% 2

26.7% 11

Free Cash Flow

~$8.6B (2024 base) 12

£4.05B 10

$12.2B (Op. Cash) 13

JPY 272.7B 14

Net Revenue

$20.14B 9

£25.6B 15

$40.65B 1

JPY 3,467.7B 14

Dividend Yield (Est.)

6.87% 7

5.70% 15

3.20% 6

5.40% 11

Smoke-Free Revenue %

~15% (Oral/Vape) 9

18.2% 10

41.5% 1

~4% (RRP) 14

The pricing power in the combustible segment remains the critical stabilizer. In 2025, Japan Tobacco reported a 10.8% pricing contribution, which more than offset a 2.7% industry-wide volume decline.11 This allows for the maintenance of high dividend payout ratios—often targeted at 75% of adjusted diluted EPS—while simultaneously reducing net debt to EBITDA ratios toward 2.0x, a common target across the sector to maintain investment-grade ratings during the transition.1


3. The 10-Asset Nicotine Portfolio

A balanced nicotine transition portfolio requires exposure to global leaders, regional innovators, and pharmaceutical hedges. Each asset is evaluated on its ability to generate durable cash flows from legacy operations while aggressively capturing share in the smoke-free categories.


Asset 1: Philip Morris International (PMI)

PMI is the vanguard of the nicotine transition. In 2025, the company’s smoke-free business generated approximately $17 billion, or 41.5% of total net revenues.2 The growth is underpinned by the IQOS heated tobacco system and the rapid expansion of ZYN nicotine pouches in the U.S. market, where shipment volumes grew by 37% in 2025.6 PMI’s 2026–2028 targets include a 6–8% organic net revenue CAGR and an 8–10% organic operating income CAGR, driven by high-single to low-teen volume growth in smoke-free products.1


Asset 2: Altria Group (MO)

Altria represents the "U.S. Value" play. With an adjusted OCI margin of over 60%, Altria generates the highest margins in the global industry.9 While its combustible volumes declined by 10.2% in the second quarter of 2025, its smoke-free initiatives, including the "on!" nicotine pouch and the NJOY e-vapor acquisition, are gaining traction.7 The 2025 authorization of "on! PLUS" by the FDA marks a significant milestone in its "Vision 2028" strategy to dominate the U.S. oral nicotine space.9


Asset 3: British American Tobacco (BAT)

BAT employs a multi-category approach, leading in vapor (Vuse), heated tobacco (glo), and modern oral (Velo). In 2025, smokeless brands added 4.7 million new consumers, bringing the total to 34.1 million.10 Modern oral products, particularly Velo Plus in the U.S., delivered triple-digit revenue growth and reached category contribution profitability within one year of launch.20 BAT aims to reduce leverage to within 2.0-2.5x by 2026, supported by a 100% adjusted cash conversion rate.10


Asset 4: Imperial Brands (IMB)

Imperial has successfully stabilized its market share in its five priority markets while achieving 13.7% growth in NGP net revenue during 2025.22 Its strategy is focused on selective geographical expansion and capital efficiency, resulting in a 20.7% return on invested capital.24 For FY 2026, Imperial has committed to a £1.45 billion share buyback, reflecting its commitment to returning high levels of free cash flow to shareholders.22


Asset 5: Japan Tobacco (JT)

JT is accelerating its RRP momentum, with Ploom heated tobacco volume increasing by nearly 40% in 2025.14 The launch of Ploom AURA has helped the company achieve a 15.5% share of the Japanese HTS market.26 JT’s 2026–2028 plan includes investing approximately JPY 800 billion into its tobacco business, with RRP as the top priority to build a presence across 80% of global heated tobacco demand.16


Asset 6: Vector Group (Incorporated into JT)

The acquisition of Vector Group by Japan Tobacco for $2.4 billion in late 2024 significantly altered the U.S. landscape. By increasing JT's U.S. market share from 2.3% to 8%, it provided a critical distribution network for the eventual launch of JT’s RRP portfolio in the world’s most profitable nicotine market.27 Vector’s integration is expected to be earnings-accretive from 2025 onward.27


Asset 7: Turning Point Brands (TPB)

TPB is a mid-cap "pure-play" transition asset. Its Modern Oral segment, featuring the FRE and ALP brands, saw net sales surge 266% in Q4 2025, now accounting for 34% of total company sales.28 This pivot from legacy chewing tobacco (Stoker's) and rolling papers (Zig-Zag) to white nicotine pouches demonstrates the agility of smaller players in capturing shifting consumer preferences.28


Asset 8: RLX Technology (RLX)

As the leading branded e-vapor company in China, RLX has successfully diversified into international markets, which now represent 76.5% of its revenue.32 In fiscal year 2025, net revenues rose 44.0% to RMB 3.96 billion, fueled by market recovery in Mainland China and strategic investments in Europe.32 RLX maintains a strong cash position of RMB 15.7 billion, allowing for consistent share repurchases.34


Asset 9: Kenvue (KVUE)

Kenvue provides a pharmaceutical entry into the nicotine transition through its world-leading NRT brand, Nicorette. While Kenvue’s overall organic sales declined by 2.2% in 2025, its "Self Care" segment grew 4.2% in Q4, driven by strong performance in international markets.36 Kenvue acts as a lower-risk play on the total cessation segment of the nicotine market, benefiting from government-funded quit-smoking programs.36


Asset 10: Dr. Reddy’s Laboratories (RDY) / Haleon (HLN)

This asset pair represents the strategic realignment of pharmaceutical nicotine. In 2024, Haleon divested its international NRT business (excluding the U.S.) to Dr. Reddy's for £500 million.40 Dr. Reddy's now controls the Nicotinell brand across 30+ countries, integrating it into its global OTC wellness portfolio.43 This transition allows Haleon to focus on "growth and agility" while Dr. Reddy's builds a dominant position in the medically-certified cessation market.40


4. Future of Smokeless Nicotine: Category Dynamics

The post-combustion era is characterized by three primary technological platforms, each with distinct adoption curves and margin profiles.


Heated Tobacco Systems (HTS)

Heated tobacco is the "closest to cigarette" alternative, favored by adult smokers seeking a familiar ritual. PMI’s IQOS remains the global benchmark, available in 106 markets with an estimated 43 million consumers.2 The technology’s future involves further premiumization, such as the IQOS ILUMA, and expansion into highly competitive markets like Japan and Taiwan.2 JT is also scaling its Ploom platform, targeting 40 markets by the end of 2026.27


Modern Oral Nicotine Pouches

Nicotine pouches represent the fastest-growing category due to their high discretion and lack of electronic hardware. The U.S. market is the epicenter of this growth, with ZYN (PMI), on! (Altria), and Velo (BAT) engaged in intense retail competition.6 The category is moving toward "modified risk" status, with Swedish Match (PMI) currently seeking FDA authorization to claim that ZYN puts consumers at a "lower risk of mouth cancer, heart disease, and lung cancer".8


Electronic Vapor (E-vapor)

The e-vapor category is currently defined by a battle between regulated pod systems and illicit, flavored disposables. In the U.S., brands like NJOY (Altria) and Vuse (BAT) are working to clear the marketplace of unauthorized products through increased FDA enforcement and "ACE Submission Tracking" rules that link imports directly to PMTA status.5 In China, RLX Technology has set a "global blueprint" for expansion, capturing over 20% of the specialty store channel in key regions.33

Nicotine Product Category Forecasts 2025-2030


Category

2025 Market Size (Est.)

Forecasted CAGR

Growth Driver

HTS

$49.1B (Global) 48

10-12%

Conversion of heavy smokers in Asia/Europe 48

Nicotine Pouches

$1.46B (Gum/Pouch focus) 49

9.93%

Discretion and convenience in North America 49

E-Cigarettes

$22.37B (Retailer segment) 50

18.6%

Rapid innovation and adoption among younger ATC 50

Pharma NRT

$3.07B 38

4.9-12.6%

Public health integration and insurance coverage 38

5. Nicotine and Human Performance: Emerging Research Themes

A significant second-order theme in the Nicotine Transition is the potential for nicotine to be reclassified not just as an alternative to smoking, but as a cognitive and physical "biohack." This research is gaining traction in elite sports and professional environments where focus and stamina are paramount.


Scientific studies conducted as part of the WADA 2021 monitoring program have explored the ergogenic effects of nicotine.52 While results are varied, certain cohorts demonstrate significant improvements. For example, a research project showed a 13.1% increase in "time to exhaustion" (TTE) due to snus administration, which could be associated with nicotine’s ability to maintain an "allostatic state" during physical stress.53


Physiological Impacts of Nicotine Administration

  • Cognitive Enhancement: Nicotine is reported to increase alertness, improve coordination, and enhance cognitive performance through sympathetic stimulation.53

  • Anaerobic Performance: A study of oral-dispersible nicotine strips (5 mg) reported significantly greater peak and average power output in repeat Wingate tests.52

  • Endurance and Heat Stress: Transdermal nicotine administration has been shown to improve cycling TTE in moderate temperatures, though it may increase the risk of heat illness in temperatures above 30°C by reducing skin blood flow.55

  • Perception of Effort: Several studies indicate that nicotine can reduce the "Rate of Perceived Exertion" (RPE) and lower the perception of pain intensity, potentially allowing athletes to push past previous physical barriers.52


The high prevalence of nicotine use among elite athletes—estimated at 25-50% in some disciplines—suggests that the transition away from combustion will unlock more of these "clean" nicotine use cases.56 If nicotine can be fully detached from the social stigma of smoking, its addressable market could expand into the broader "nootropics" and performance-supplement sectors.


6. Illicit Cigarette Consumption: The Shadow Market Challenge

The successful transition to a post-combustion era is heavily dependent on the effective regulation of the legacy combustible market. In many developed and emerging markets, excessive excise tax increases have led to a surge in illicit trade, which paradoxically keeps consumers tethered to cigarettes by providing a cheap, unregulated alternative.58


The European Epicenter

According to a 2024 KPMG study, EU smokers consumed 38.9 billion illicit cigarettes, a 10.8% increase over the previous year. This represents 9.2% of total consumption, with governments losing €14.9 billion in tax revenues.60 France remains the single largest illicit market in Europe, with 18.7 billion illicit cigarettes consumed (37.6% of total consumption), driven by a massive increase in counterfeit goods.58


The Australian Case Study

Australia serves as a warning for policymakers. Decade-long excise increases have widened the price gap between legal and illicit cigarettes from $11 to $47.59 Consequently, the illicit market share is estimated at 50-60% as of 2024-2025.59 Modeling by Oxford Economics suggests that by 2028-2029, nine out of every ten cigarettes in Australia could be illicit if current trajectories hold.59

Illicit Trade Trends and Impacts (2024–2025)


Market

Illicit Share

Annual Tax Loss

Key Driver

France

37.6%

€9.4B 60

Counterfeit proliferation and high price 58

Netherlands

17.9%

€0.9B 60

Doubled in one year after tax hikes 60

Romania

5.9%

€268M 63

Slight increase in late 2024 63

Australia

50-60%

$67B (10-yr cumulative) 59

Extreme price sensitivity and cost-of-living 59

Philippines

High

Php 25.5B (2023) 64

Tax stamp violations and "overshifting" 64

In Southeast Asia, countries like Indonesia, the Philippines, and Vietnam remain dominated by traditional cigarettes, with a combined unit volume of over 490 billion sticks.48 In these markets, the illicit trade is often driven by "overshifting," where companies raise prices beyond tax-related adjustments to maintain profitability, thereby inadvertently pushing low-income consumers toward unregulated black markets.64


7. Risks and Regulatory Challenges

The nicotine transition is a high-stakes regulatory navigation. The ability of companies to secure market authorizations and modified risk orders will determine the winners of the next decade.


The FDA PMTA and Pilot Program

The U.S. FDA has transitioned from concept to execution with its "Streamlined Nicotine Pouch Pilot," designed to review applications more efficiently while maintaining scientific standards.5 In December 2025, Altria's "on! PLUS" became the first products authorized under this pilot, reflecting a new "record time" for scientific review.19 However, marketing denial orders (MDOs) and refuse-to-file (RTF) decisions continue to be used as a roadmap for targeted enforcement against unauthorized disposables.5


MRTP Claims and Public Perception

Philip Morris International’s pursuit of MRTP status for ZYN is a critical test case. The Tobacco Products Scientific Advisory Committee (TPSAC) met in early 2026 to discuss Swedish Match’s claims.8 A positive MRTP order would allow the company to market its products as lower risk for chronic diseases, effectively institutionalizing the "Nicotine Transition" in the eyes of health authorities and consumers.8

Global Fiscal Volatility

Governments are increasingly looking to alternative nicotine products for revenue. In 2026, Italy implemented a progressive fiscal strategy through 2028, with excise duty increases affecting both traditional cigarettes and alternative products.66 While traditional cigarettes saw a price increase of €0.15 per pack in 2026, alternative products like heated tobacco saw more moderate increases, maintaining a price incentive for switching.66


8. Investment Outlook: Valuation and Terminal Value

The nicotine industry is at a valuation crossroads. Legacy tobacco giants are trading at historically low multiples, while the "Transition Leaders" are beginning to command premiums as they demonstrate the viability of the smoke-free model.


Portfolio Evaluation: Transition Strategy vs. Cash Flow Durability

  • Transition Leaders (PMI, RLX, TPB): These companies are valued on their ability to capture new market share and expand margins through "mix upgrades." PMI’s P/E ratio of ~24x reflects its dominance in HTS and oral nicotine, while RLX’s international expansion blueprint is seen as a hedge against domestic regulatory shifts.6

  • Cash Flow Anchors (Altria, BAT, Imperial): These assets provide the yield floor. With dividend yields between 5% and 7%, they are essential for total return strategies. Their valuation relies on the "bridge" — the ability of cigarette pricing to fund buybacks and NGP expansion without triggering a terminal collapse in volume.9

  • Consolidation and Pharma Hedges (Japan Tobacco, Kenvue, Dr. Reddy’s): JT’s acquisition of Vector Group and Dr. Reddy’s entry into the NRT space signify a broader trend of cross-sector consolidation. As tobacco and pharma converge on "clean nicotine," these assets offer unique defensive characteristics and integration synergies.27


Conclusion: The New Nicotine Algorithm

The investment algorithm for the post-combustion era is no longer just "Volume - Pricing = FCF." It is now "Pricing Power + RRP Adoption - Illicit Erosion = Terminal Value Growth." Success requires a 2.0x leverage target to maintain capital flexibility, a 75% dividend payout to satisfy income mandates, and a portfolio that is at least 40% smoke-free by 2026.1


Investors should prioritize assets like PMI and Altria, which are successfully navigating the FDA’s streamlined pathways, while using JT and KT&G for exposure to the emerging middle-class consumers in Asia.2 


The pharmaceutical segment, led by Kenvue and the newly fortified Dr. Reddy’s, provides a hedge against the most aggressive regulatory outcomes.36 Ultimately, the Nicotine Transition is a story of a legacy industry "rewiring" itself for a future where combustion is obsolete, but nicotine remains a staple of human consumption and performance.1

Works cited

  1. Philip Morris (NYSE: PM) outlines 2026-28 smoke-free growth and EPS goals, accessed March 15, 2026, https://www.stocktitan.net/sec-filings/PM/8-k-philip-morris-international-inc-reports-material-event-79f7ff888a72.html

  2. We're delivering a smoke free future, faster | Philip Morris International (PMI.com), accessed March 15, 2026, https://www.pmi.com/progress/

  3. PMI's Integrated Report 2024 - Philip Morris International, accessed March 15, 2026, https://www.pmi.com/content/dam/pmicom/global/docs/pmi-sustainability/pmi-integrated-report-2024.pdf

  4. How the Energy Transition Is Rewiring Global Trade: 2050 Scenarios | BloombergNEF, accessed March 15, 2026, https://about.bnef.com/insights/clean-energy/how-the-energy-transition-is-rewiring-global-trade-2050-scenarios/

  5. What 2026 Signals for the US Nicotine and ENDS Marketplace - Broughton Group, accessed March 15, 2026, https://www.broughton-group.com/blog/what-2026-signals-for-the-us-nicotine-and-ends-marketplace

  6. Is Philip Morris International's Smoke-Free Strategy Paying Off, accessed March 15, 2026, https://www.kavout.com/market-lens/is-philip-morris-international-s-smoke-free-strategy-paying-off

  7. Earnings call transcript: Altria beats Q2 2025 forecasts, stock rises - Investing.com, accessed March 15, 2026, https://www.investing.com/news/transcripts/earnings-call-transcript-altria-beats-q2-2025-forecasts-stock-rises-93CH-4160627

  8. Advisory Committee Meeting Scheduled on Modified Risk Tobacco Product Applications for ZYN Nicotine Pouch Products | FDA, accessed March 15, 2026, https://www.fda.gov/tobacco-products/ctp-newsroom/advisory-committee-meeting-scheduled-modified-risk-tobacco-product-applications-zyn-nicotine-pouch

  9. Altria Reports 2025 Fourth-Quarter and Full-Year Results; Provides 2026 Earnings Guidance - Investors At-A-Glance, accessed March 15, 2026, https://investor.altria.com/press-releases/news-details/2026/Altria-Reports-2025-Fourth-Quarter-and-Full-Year-Results-Provides-2026-Earnings-Guidance/default.aspx

  10. Preliminary results for the year ended 31 December 2025 - British American Tobacco, accessed March 15, 2026, https://www.bat.com/content/dam/batcom/global/main-nav/investors-and-reporting/results-centre/pdf/FY_2025_Announcement.pdf

  11. Japan Tobacco FY2025 slides: Record results driven by pricing power and RRP growth, accessed March 15, 2026, https://www.investing.com/news/company-news/japan-tobacco-fy2025-slides-record-results-driven-by-pricing-power-and-rrp-growth-93CH-4502177

  12. Altria Free Cash Flow 2012-2025 | MO - Macrotrends, accessed March 15, 2026, https://www.macrotrends.net/stocks/charts/MO/altria/free-cash-flow

  13. Philip Morris targets 5–7% organic net revenue growth for 2026 while expanding smoke-free leadership - Seeking Alpha, accessed March 15, 2026, https://seekingalpha.com/news/4548693-philip-morris-targets-5-7-percent-organic-net-revenue-growth-for-2026-while-expanding-smoke

  14. 2025 Earnings Report - JT, accessed March 15, 2026, https://www.jt.com/investors/results/forecast/pdf/2025/Full_Year/20260212_06.pdf

  15. British American Tobacco (FY Results): in-line, guidance unchanged | HL, accessed March 15, 2026, https://www.hl.co.uk/shares/share-research/british-american-tobacco-fy-results-in-line-guidance-unchanged

  16. 2025 Full Year Results & 2026 Forecast (All Presentation), accessed March 15, 2026, https://finance-frontend-pc-dist.west.edge.storage-yahoo.jp/disclosure/20260212/20260212556024.pdf

  17. Philip Morris (PM) Q4 2025 Earnings Transcript | The Motley Fool, accessed March 15, 2026, https://www.fool.com/earnings/call-transcripts/2026/02/06/philip-morris-pm-q4-2025-earnings-transcript/

  18. Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share, accessed March 15, 2026, https://www.pmi.com/investor-relations/press-releases-and-events/press-releases-overview/press-release-details/?newsId=29746

  19. FDA Authorizes Marketing of Six Nicotine Pouches - NACS, accessed March 15, 2026, https://www.convenience.org/Media/Daily/2025/December/19/FDA-Authorizes-Marketing-of-Six-Nicotine-Pouches

  20. Preliminary results for the year ended 31 ... - British American Tobacco, accessed March 15, 2026, https://www.bat.com/media/press-releases/_2026/february/preliminary-results-for-the-year-ended-31-december-2025

  21. British American Tobacco - 2025 Full Year Pre-Close Trading Update - BAT, accessed March 15, 2026, https://www.bat.com/media/press-releases/_2025/december/2025-full-year-pre-close-trading-update

  22. Full Year Results 2025 - Imperial Brands, accessed March 15, 2026, https://www.imperialbrandsplc.com/investor-hub/full-year-results-2025

  23. Full Year Results | 18 November 2025 - Imperial Brands, accessed March 15, 2026, https://www.imperialbrandsplc.com/content/dam/imperialbrands/corporate/documents/investor-hub/results/2025/IMB-FY25-Results-Slides.pdf.downloadasset.pdf

  24. Financial performance - Imperial Brands, accessed March 15, 2026, https://www.imperialbrandsplc.com/investor-hub/financial-performance

  25. Imperial Brands demonstrates 'consistent growth' in full-year results, accessed March 15, 2026, https://www.corporatefinancenews.net/Imperial-Brands-demonstrates-consistent-growth-in-full-year-results.php

  26. JT Reports Strong Q3 2025 Results, Raises Full-Year Forecasts - Tobacco Reporter, accessed March 15, 2026, https://tobaccoreporter.com/2025/10/30/jt-reports-strong-q3-2025-results-raises-full-year-forecasts/

  27. What is Growth Strategy and Future Prospects of Japan Tobacco Company? - Matrix BCG, accessed March 15, 2026, https://matrixbcg.com/blogs/growth-strategy/jti

  28. Turning Point Reports 31% Profit Increase for FY25 - Tobacco Reporter, accessed March 15, 2026, https://tobaccoreporter.com/2026/03/02/turning-point-reports-31-profit-increase-for-fy25/

  29. Turning Point Brands Announces Fourth Quarter and Full Year 2025 Results, accessed March 15, 2026, https://www.businesswire.com/news/home/20260302348296/en/Turning-Point-Brands-Announces-Fourth-Quarter-and-Full-Year-2025-Results

  30. Earnings call transcript: Turning Point Brands' Q4 2025 results show strong revenue growth, accessed March 15, 2026, https://in.investing.com/news/transcripts/earnings-call-transcript-turning-point-brands-q4-2025-results-show-strong-revenue-growth-93CH-5266875

  31. Turning Point Brands Announces Fourth Quarter and Full Year 2025 Results - TradingView, accessed March 15, 2026, https://www.tradingview.com/news/tradingview:2700c936d26e7:0-turning-point-brands-announces-fourth-quarter-and-full-year-2025-results/

  32. Rlx Technology Stock Price, News & Analysis, accessed March 15, 2026, https://www.stocktitan.net/overview/RLX/

  33. RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results - Mar 13, 2026, accessed March 15, 2026, https://ir.relxtech.com/2026-03-13-RLX-Technology-Announces-Unaudited-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results

  34. RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results - PR Newswire, accessed March 15, 2026, https://www.prnewswire.com/news-releases/rlx-technology-announces-unaudited-fourth-quarter-and-fiscal-year-2025-financial-results-302713240.html

  35. Press Release: RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results - Moomoo, accessed March 15, 2026, https://www.moomoo.com/news/post/66836018/press-release-rlx-technology-announces-unaudited-fourth-quarter-and-fiscal

  36. Kenvue Inc. - Financials & reports - Quarterly results - Investor Relations, accessed March 15, 2026, https://investors.kenvue.com/financials-reports/quarterly-results/default.aspx

  37. Kenvue Reports Fourth Quarter and Full Year 2025 Results, accessed March 15, 2026, https://investors.kenvue.com/financial-news/news-details/2026/Kenvue-Reports-Fourth-Quarter-and-Full-Year-2025-Results/

  38. Nicotine Replacement Therapy [NRT] Market Size, Share, 2034 - Fortune Business Insights, accessed March 15, 2026, https://www.fortunebusinessinsights.com/nicotine-replacement-therapy-nrt-market-103362

  39. Kenvue Reports Third Quarter 2025 Results | Nasdaq, accessed March 15, 2026, https://www.nasdaq.com/press-release/kenvue-reports-third-quarter-2025-results-2025-11-03

  40. Haleon has divested its nicotine replacement therapy (“NRT”) business outside of the US to Dr. Reddy's Laboratories SA. - Grant Thornton UK, accessed March 15, 2026, https://www.grantthornton.co.uk/services/deals/our-credentials/grant-thornton-advises-haleon-plc/

  41. accessed March 15, 2026, https://www.angelone.in/news/share-market/dr-reddys-acquires-haleons-nicotine-replacement-therapy-brand#:~:text=Reddy's%20Acquires%20Haleon's%20Nicotine%20Replacement%20Therapy%20Brand%20for%20%C2%A3500%20Million,-Updated%20on%3A%204&text=53%20pm%20IST-,Dr.,States%20for%20GBP%20500%20million.

  42. TOP NEWS: Haleon sells NRT business outside of US for £500 million | AJ Bell, accessed March 15, 2026, https://www.ajbell.co.uk/news/articles/top-news-haleon-sells-nrt-business-outside-us-ps500-million

  43. Dr Reddy's completes acquisition of Haleon's NRT portfolio - ET Pharma, accessed March 15, 2026, https://pharma.economictimes.indiatimes.com/news/pharma-industry/dr-reddys-completes-acquisition-of-haleons-nrt-portfolio/113818945

  44. Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug ..., accessed March 15, 2026, https://www.zacks.com/stock/news/2294456/dr-reddys-rdy-to-acquire-haleons-nicotine-addiction-drug

  45. 2025 Full Year Results - Haleon, accessed March 15, 2026, https://www.haleon.com/news/press-releases/financial/2026/2025-full-year-results

  46. Dr Reddy's completes acquisition of Haleon's NRT portfolio - The Economic Times, accessed March 15, 2026, https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-completes-acquisition-of-haleons-nrt-portfolio/articleshow/113818231.cms

  47. Earnings call transcript: RLX Technology Q4 2025 results show mixed performance, accessed March 15, 2026, https://ng.investing.com/news/transcripts/earnings-call-transcript-rlx-technology-q4-2025-results-show-mixed-performance-93CH-2391403

  48. Status Of Tobacco Products In 2026 In ASEAN - TobaccoWatch, accessed March 15, 2026, https://tobaccowatch.seatca.org/index.php/2026/01/29/status-of-tobacco-products-in-2026-in-asean/

  49. Nicotine Gum Market Size, Competitive Landscape 2026 – 2031 - Mordor Intelligence, accessed March 15, 2026, https://www.mordorintelligence.com/industry-reports/nicotine-gum-market

  50. Smoking Cessation And Nicotine De-addiction Market Growth Analysis - Size and Forecast 2026-2030 | Technavio, accessed March 15, 2026, https://www.technavio.com/report/smoking-cessation-and-nicotine-de-addiction-market-industry-analysis

  51. Nicotine Replacement Therapy Market Size & Share - ReAnIn, accessed March 15, 2026, https://www.reanin.com/reports/nicotine-replacement-therapy-market

  52. The Effect of High Nicotine Dose on Maximum Anaerobic Performance and Perceived Pain in Healthy Non-Smoking Athletes: Crossover Pilot Study - MDPI, accessed March 15, 2026, https://www.mdpi.com/1660-4601/20/2/1009

  53. Effects of snus administration on sport performance - Wada-ama.org, accessed March 15, 2026, https://www.wada-ama.org/en/resources/scientific-research/effects-snus-administration-sport-performance

  54. The effects of nicotine withdrawal on exercise-related physical ability and sports performance in nicotine addicts: a systematic review and meta-analysis - Taylor & Francis, accessed March 15, 2026, https://www.tandfonline.com/doi/full/10.1080/15502783.2024.2302383

  55. Nicotine, exercise and heat stress: Performance benefits, health risks and implications for the Prohibited List - WADA, accessed March 15, 2026, https://www.wada-ama.org/en/resources/scientific-research/nicotine-exercise-and-heat-stress-performance-benefits-health-risks

  56. An anti-doping perspective on nicotine detection in the peri-exercise period in a cohort of trained male cyclists - PMC, accessed March 15, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8562138/

  57. Should We be Concerned with Nicotine in Sport? Analysis from 60,802 Doping Control Tests in Italy - PMC, accessed March 15, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9951140/

  58. Illicit Cigarettes in European Union at Highest Level Since 2015, KPMG Study Shows, accessed March 15, 2026, https://www.nasdaq.com/press-release/illicit-cigarettes-european-union-highest-level-2015-kpmg-study-shows-2025-06-11

  59. Reset excise and strengthen enforcement to cut illicit tobacco - Oxford Economics, accessed March 15, 2026, https://www.oxfordeconomics.com/resource/reset-excise-and-strengthen-enforcement-to-cut-illicit-tobacco/

  60. Illicit Cigarettes in European Union at Highest Level Since 2015, KPMG Study Shows, accessed March 15, 2026, https://via.ritzau.dk/pressemeddelelse/14446663/illicit-cigarettes-in-european-union-at-highest-level-since-2015-kpmg-study-shows?publisherId=90456&lang=en

  61. Illicit cigarette trade surges in France and the Netherlands, raising alarm over policy failures, accessed March 15, 2026, https://www.eureporter.co/health/2025/06/17/illicit-cigarette-trade-surges-in-france-and-the-netherlands-raising-alarm-over-policy-failures/

  62. Oxford Report: Tobacco Tax Fills Chalmers' Budget Gap | Mirage News, accessed March 15, 2026, https://www.miragenews.com/oxford-report-tobacco-tax-fills-chalmers-budget-1620647/

  63. KPMG Report: Highest Level of Illicit Cigarette Consumption in the EU in the Last 10 Years. Illicit cigarette consumption in Romania, annual average of 5.9% in 2024, accessed March 15, 2026, https://business-review.eu/international/kpmg-report-highest-level-of-illicit-cigarette-consumption-in-the-eu-in-the-last-10-years-illicit-cigarette-consumption-in-romania-annual-average-of-5-9-in-2024-284835

  64. New Report Flags Possible Tobacco Industry Role in Illicit Cigarette Trade in the Philippines, accessed March 15, 2026, https://exposetobacco.org/news/big-tobacco-illicit-trade-philippines/

  65. FDA Authorizes 6 Nicotine Pouch Products, Completing Review in Record Time, accessed March 15, 2026, https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-6-nicotine-pouch-products-completing-review-record-time

  66. 2026: Europe raises taxes on tobacco and nicotine. Switzerland looks the other way., accessed March 15, 2026, https://www.at-schweiz.ch/en/at-blog/2026-europe-raises-taxes-on-tobacco-and-nicotine/

KT&G enters era of KRW 6 Trillion annual revenue in 2025, operating profit break KRW 1.3 trillion mark - PR Newswire, accessed March 15, 2026, https://www.prnewswire.com/news-releases/ktg-enters-era-of-krw-6-trillion-annual-revenue-in-2025--operating-profit-break-krw-1-3-trillion-mark-302679955.html

 
 
 

Comments

©2025 by Acacia Investment Research.

bottom of page